What is EMMAUS LIFE SCIENCES INC's earnings per share (EPS)?

EMMAUS LIFE SCIENCES INC (EMMA) reported diluted earnings per share of -$0.12 for fiscal year 2025. This represents a -20.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

EMMAUS LIFE SCIENCES INC (EMMA) Financials

EMMA

FY2025 annual

Revenue $12.5M -25.2% YoY

Net Income -$7.5M -16.1% YoY

EPS (Diluted) -$0.12 -20.0% YoY

Free Cash Flow -$12K +99.5% YoY

Market Cap $4.1M as of Oct 16, 2026

Price / Sales 0.3x on $15.5M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EMMA SEC filings page.

EMMAUS LIFE SCIENCES INC (EMMA) reported $12.5M in revenue for fiscal year 2025, down 25.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EMMA FY2025 2026-10-03

High gross margins have not translated into durable earnings because shrinking sales and interest costs consume the operating result.

In FY2023, a 95.5% gross margin supported $3.5M of operating profit. By FY2025, gross margin remained above 93%, yet operating profit was nearly zero as revenue contracted; the pattern points to lost scale rather than a cost-of-goods problem.

FY2025 reported a net loss of $7.5M while operating cash flow was only -$11K. With free cash flow also near zero at -$12K, accounting losses were not a close measure of that year's cash movement, although the company remained unprofitable.

The balance sheet shows short-term financial strain: FY2025 current assets were $7.7M against $69.1M of current liabilities. That mismatch appears in the 0.1x current ratio, while liabilities of $85.0M exceeded assets of $21.4M, leaving a negative equity position.

Financial Health Signals

Financial health score not available

EMMAUS LIFE SCIENCES INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-20.43

EMMAUS LIFE SCIENCES INC scores -20.43, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.1M) relative to total liabilities ($85.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

EMMAUS LIFE SCIENCES INC passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

EMMAUS LIFE SCIENCES INC reported a net loss of $7.5M while operations used $11K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

0.03x

EMMAUS LIFE SCIENCES INC earns $0.03 in operating income for every $1 of interest expense ($231K vs $7.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.3M

YoY+124.3%

QoQ+218.8%

5Y CAGR-0.5%

10Y CAGR+76.9%

EMMAUS LIFE SCIENCES INC generated $6.3M in revenue in Q2 2026. This represents an increase of 124.3% from the same quarter a year earlier. Against the prior quarter it is up 218.8%.

EBITDA

$3.8M

YoY+1139.6%

QoQ+570.9%

5Y CAGR+50.4%

EMMAUS LIFE SCIENCES INC's EBITDA was $3.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1139.6% from the same quarter a year earlier. Against the prior quarter it is up 570.9%.

Net Income

$1.3M

YoY+218.0%

QoQ+140.1%

5Y CAGR-11.7%

EMMAUS LIFE SCIENCES INC reported $1.3M in net income in Q2 2026. This represents an increase of 218.0% from the same quarter a year earlier. Against the prior quarter it is up 140.1%.

EPS (Diluted)

$0.02

YoY+200.0%

QoQ+140.0%

5Y CAGR-16.7%

EMMAUS LIFE SCIENCES INC earned $0.02 per diluted share (EPS) in Q2 2026. This represents an increase of 200.0% from the same quarter a year earlier. Against the prior quarter it is up 140.0%.

Cash & Balance Sheet

Cash & Debt

$2.8M

YoY+216.9%

QoQ+161.9%

5Y CAGR+10.9%

10Y CAGR+20.6%

EMMAUS LIFE SCIENCES INC held $2.8M in cash against $25.0M in long-term debt as of Q2 2026.

Shares Outstanding

70M

YoY+9.9%

QoQ0.0%

5Y CAGR+7.3%

10Y CAGR-4.2%

EMMAUS LIFE SCIENCES INC had 70M shares outstanding in Q2 2026. This represents an increase of 9.9% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

94.6%

YoY-0.1pp

QoQ+3.0pp

5Y change+1.2pp

10Y change+1.7pp

EMMAUS LIFE SCIENCES INC's gross margin was 94.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.0 percentage points.

Operating Margin

60.0%

YoY+73.1pp

QoQ+101.5pp

5Y change+52.6pp

EMMAUS LIFE SCIENCES INC's operating margin was 60.0% in Q2 2026, reflecting core business profitability. This is up 73.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 101.5 percentage points.

Net Margin

21.2%

YoY+61.5pp

5Y change-17.2pp

EMMAUS LIFE SCIENCES INC's net profit margin was 21.2% in Q2 2026, showing the share of revenue converted to profit. This is up 61.5 percentage points from the same quarter a year earlier.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$116K

YoY+107.1%

QoQ+190.0%

5Y CAGR-31.2%

EMMAUS LIFE SCIENCES INC invested $116K in research and development in Q2 2026. This represents an increase of 107.1% from the same quarter a year earlier. Against the prior quarter it is up 190.0%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

EMMA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EMMA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$15.5M	$12.5M-25.2%	$16.7M-43.7%	$29.6M+60.9%	$18.4M-10.8%	$20.6M-11.0%	$23.2M+1.8%	$22.8M+38.2%	$16.5M+12708.6%	$129K+51.0%	$85K-15.0%	$100K-25.9%	$135K+3.2%	$131K	N/A	$746K
Cost of Revenue	$994K	$857K-28.6%	$1.2M-10.5%	$1.3M-48.1%	$2.6M-21.9%	$3.3M+47.3%	$2.2M+105.5%	$1.1M+10.2%	$993K+1756.1%	$54K+872.7%	$6K+12.2%	$5K-93.3%	$73K	N/A	N/A	N/A
Gross Profit	$14.5M	$11.6M-25.0%	$15.5M-45.3%	$28.3M+78.8%	$15.8M-8.6%	$17.3M-17.3%	$20.9M-3.4%	$21.7M+40.0%	$15.5M+20521.3%	$75K-5.8%	$80K-16.4%	$95K+53.3%	$62K	N/A	N/A	N/A
R&D Expenses	$237K	$313K-52.4%	$657K-44.7%	$1.2M-31.1%	$1.7M-58.0%	$4.1M+70.7%	$2.4M+10.3%	$2.2M+26.7%	$1.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$7.0M	$8.2M-23.5%	$10.7M-28.2%	$14.9M+13.1%	$13.2M-2.0%	$13.4M-1.8%	$13.7M-19.6%	$17.0M-2.6%	$17.5M+280.4%	$4.6M+81.4%	$2.5M+56.8%	$1.6M-20.7%	$2.0M-20.4%	$2.6M	N/A	$3.2M
Operating Income	$4.5M	$231K+112.2%	-$1.9M-153.5%	$3.5M+153.8%	-$6.6M-7.5%	-$6.1M-19050.0%	-$32K+99.3%	-$4.5M+46.6%	-$8.5M-19.0%	-$7.1M	N/A	-$2.6M+30.6%	-$3.8M+9.1%	-$4.2M	N/A	N/A
EBITDA	N/A	$270K+114.4%	-$1.9M-152.4%	$3.6M+154.7%	-$6.5M-7.6%	-$6.1M-21775.0%	$28K+100.6%	-$4.4M+47.1%	-$8.4M-19.0%	-$7.1M	N/A	-$2.6M+30.6%	-$3.8M+9.1%	-$4.2M	N/A	N/A
Interest Expense	$7.9M	$7.1M+29.9%	$5.5M-25.6%	$7.4M+47.3%	$5.0M+61.7%	$3.1M-48.2%	$6.0M-78.3%	$27.6M+21.2%	$22.8M+345293.9%	$7K	N/A	$257K+2100.0%	$12K-99.1%	$1.3M	N/A	N/A
Income Tax	$598K	$9K-69.0%	$29K+149.2%	-$59K-198.3%	$60K+140.0%	$25K+106.6%	-$381K-332.3%	$164K+320.5%	$39K+1400.0%	$3K+30.0%	$2K-60.0%	$5K-3.8%	$5K+550.0%	$800-57.9%	$2K+46.2%	$1K
Net Income	-$6.0M	-$7.5M-16.1%	-$6.5M-72.9%	-$3.7M+64.9%	-$10.6M+33.4%	-$15.9M-1277.7%	$1.4M+102.5%	-$54.8M+24.4%	-$72.6M-920.5%	-$7.1M	N/A	N/A	-$2.7M	N/A	N/A	N/A
EPS (Basic)	N/A	-$0.12-20.0%	-$0.10-42.9%	-$0.07+66.7%	-$0.21+34.4%	-$0.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.14+92.3%	-$1.81+61.8%	-$4.74
EPS (Diluted)	-$0.09	-$0.12-20.0%	-$0.10-42.9%	-$0.07+66.7%	-$0.21+34.4%	-$0.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.14	-$1.81	-$4.74
Diluted Shares (Avg)	N/A	64M+1.3%	63M+19.1%	53M+7.4%	49M+0.4%	49M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	76M	2M	2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$6.3M+124.3%	$2.0M-17.6%	$3.9M+17.0%	$3.4M-38.3%	$2.8M-47.6%	$2.4M-4.0%	$3.3M-53.4%	$5.5M+9.2%
Cost of Revenue	$344K+129.3%	$168K-25.3%	$235K-23.9%	$247K-37.3%	$150K-37.8%	$225K-12.5%	$309K+61.8%	$394K+84.1%
Gross Profit	$6.0M+124.0%	$1.8M-16.8%	$3.6M+21.3%	$3.1M-38.4%	$2.7M-48.1%	$2.2M-3.0%	$3.0M-56.6%	$5.1M+5.8%
R&D Expenses	$116K+107.1%	$40K-77.3%	$31K-77.4%	$50K-65.8%	$56K-70.7%	$176K-3.8%	$137K-17.5%	$146K-64.7%
SG&A Expenses	$1.6M-31.8%	$1.9M-20.9%	$1.8M-21.2%	$1.7M-38.2%	$2.3M-15.6%	$2.3M-18.5%	$2.3M-25.4%	$2.8M-2.4%
Operating Income	$3.8M+1124.6%	-$823K+16.0%	$886K+259.1%	$695K-15.3%	-$370K-163.6%	-$980K+64.2%	-$557K-141.1%	$821K+3320.8%
EBITDA	$3.8M+1139.6%	-$808K+17.1%	$901K+263.2%	$710K-14.0%	-$366K-162.2%	-$975K+64.3%	-$552K-140.5%	$826K+2564.5%
Interest Expense	$1.6M-4.9%	$2.1M+69.3%	$2.3M+77.5%	$1.9M+44.3%	$1.7M+73.7%	$1.3M-34.2%	$1.3M-41.3%	$1.3M-29.9%
Income Tax	-$1K+99.8%	$4K0.0%	$16K+166.7%	$579K+58000.0%	-$590K-2003.2%	$4K+157.1%	$6K+105.4%	-$1K-102.6%
Net Income	$1.3M+218.0%	-$3.3M-43.1%	-$2.0M-11.6%	-$2.1M-213.6%	-$1.1M+48.0%	-$2.3M+46.4%	-$1.7M-244.6%	$1.8M+2626.9%
EPS (Basic)	$0.02+200.0%	-$0.05-25.0%	-$0.030.0%	-$0.03-200.0%	-$0.02+33.3%	-$0.04+42.9%	-$0.03-250.0%	$0.03
EPS (Diluted)	$0.02+200.0%	-$0.05-25.0%	-$0.030.0%	-$0.03-200.0%	-$0.02+33.3%	-$0.04+42.9%	-$0.03-250.0%	$0.03+400.0%
Diluted Shares (Avg)	121M+88.7%	70M+9.9%	N/A	64M0.0%	64M+0.8%	64M+3.3%	N/A	64M-53.8%

EMMA Balance Sheet

EMMA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$21.4M-9.2%	$23.6M-32.9%	$35.2M-27.1%	$48.2M-15.0%	$56.7M-4.7%	$59.5M+0.1%	$59.5M-21.0%	$75.3M+1134.9%	$6.1M+1090.4%	$512K-9.7%	$567K-57.6%	$1.3M-4.7%	$1.4M+1019.1%	$125K-66.1%	$370K
Current Assets	$7.7M+14.5%	$6.8M-41.2%	$11.5M+83.0%	$6.3M-30.8%	$9.1M-19.2%	$11.3M-72.7%	$41.2M-32.0%	$60.6M+964.5%	$5.7M+1316.8%	$402K-26.7%	$548K-58.1%	$1.3M-4.1%	$1.4M+1569.4%	$82K-75.1%	$329K
Cash & Equivalents	$2.1M+53.1%	$1.4M-45.5%	$2.5M+26.0%	$2.0M-11.3%	$2.3M-8.4%	$2.5M+40.6%	$1.8M-54.7%	$3.9M-28.3%	$5.4M+1612.4%	$318K-26.4%	$432K-65.2%	$1.2M-2.6%	$1.3M+16440.3%	$8K-89.5%	$74K
Short-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$27.9M-43.4%	$49.3M	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.6M-4.9%	$1.6M-4.4%	$1.7M-28.1%	$2.4M-45.8%	$4.4M-38.0%	$7.1M-11.1%	$8.0M+69.4%	$4.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.8M+6.9%	$2.6M-52.5%	$5.5M+1373.1%	$375K-63.9%	$1.0M+425.3%	$198K-90.8%	$2.1M+20.2%	$1.8M+27407.7%	$7K+27.5%	$5K-56.8%	$12K+26.9%	$9K-65.0%	$27K+114.5%	$12K-35.4%	$19K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$538K+174.6%	$196K	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$85.0M+6.2%	$80.1M-3.4%	$82.9M+0.8%	$82.3M+5.3%	$78.2M+20.9%	$64.7M-8.2%	$70.5M-27.3%	$97.0M+6162.4%	$1.5M-1.8%	$1.6M-70.8%	$5.4M+74.4%	$3.1M-13.0%	$3.6M-73.0%	$13.2M+11.9%	$11.8M
Current Liabilities	$69.1M+8.7%	$63.6M+3.3%	$61.5M+13.2%	$54.3M+46.4%	$37.1M+58.7%	$23.4M-28.8%	$32.8M-27.9%	$45.6M+2848.1%	$1.5M+0.3%	$1.5M-14.6%	$1.8M+11.6%	$1.6M-54.5%	$3.6M-73.0%	$13.2M+12.0%	$11.8M
Non-Current Liabilities	$16.0M-3.4%	$16.5M-22.9%	$21.4M-23.5%	$28.0M-31.9%	$41.1M-0.6%	$41.3M+9.6%	$37.7M-28.8%	$52.9M+1556488.2%	$3K-90.6%	$36K-99.0%	$3.6M+143.0%	$1.5M+24581.7%	$6K+20.0%	$5K-51.0%	$10K
Long-Term Debt	$27.1M-6.3%	$29.0M-5.2%	$30.6M+0.5%	$30.4M+36.2%	$22.3M+46.1%	$15.3M	N/A	$597K+7.6%	$555K	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$63.6M-12.6%	-$56.5M-18.3%	-$47.8M-40.1%	-$34.1M-58.9%	-$21.4M-315.9%	-$5.2M+53.3%	-$11.1M+49.1%	-$21.7M-577.4%	$4.5M+527.2%	-$1.1M+78.0%	-$4.8M-174.6%	-$1.8M+18.4%	-$2.2M+83.5%	-$13.1M-14.5%	-$11.4M
Retained Earnings	-$270.1M-2.9%	-$262.6M-2.5%	-$256.1M-1.5%	-$252.3M-4.6%	-$241.3M-7.2%	-$225.1M+0.5%	-$226.2M-32.0%	-$171.4M-126.5%	-$75.6M-10.4%	-$68.5M-9.5%	-$62.6M-5.7%	-$59.2M-4.7%	-$56.6M-23.9%	-$45.6M-8.1%	-$42.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$16.4M-29.9%	$18.7M-16.8%	$21.4M-9.2%	$20.8M-24.1%	$23.3M-10.0%	$22.5M-23.9%	$23.6M-32.9%	$27.3M-42.4%
Current Assets	$6.0M+19.7%	$6.0M+6.0%	$7.7M+14.5%	$4.8M-48.0%	$5.0M-44.4%	$5.7M-27.9%	$6.8M-41.2%	$9.2M-0.6%
Cash & Equivalents	$2.8M+216.9%	$1.1M-19.6%	$2.1M+53.1%	$293K-76.7%	$886K-41.9%	$1.3M-22.1%	$1.4M-45.5%	$1.3M-16.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.6M+21.0%	$1.9M+32.8%	$1.6M-4.9%	$1.2M-24.7%	$1.3M-19.3%	$1.4M-5.9%	$1.6M-4.4%	$1.6M-2.4%
Accounts Receivable	$709K-65.8%	$2.0M-0.6%	$2.8M+6.9%	$2.6M-47.0%	$2.1M-55.0%	$2.1M-31.1%	$2.6M-52.5%	$4.9M+7.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$82.5M+4.4%	$86.6M+6.8%	$85.0M+6.2%	$80.2M-1.1%	$79.0M-4.7%	$81.1M-2.5%	$80.1M-3.4%	$81.1M-3.2%
Current Liabilities	$66.1M+6.5%	$70.5M+8.7%	$69.1M+8.7%	$64.2M+0.1%	$62.1M-3.0%	$64.9M+4.0%	$63.6M+3.3%	$64.1M+5.3%
Non-Current Liabilities	$16.4M-3.2%	$16.0M-0.9%	$16.0M-3.4%	$16.1M-5.4%	$17.0M-10.3%	$16.2M-22.1%	$16.5M-22.9%	$17.0M-25.7%
Long-Term Debt	$25.0M-16.0%	$26.6M-8.4%	$27.1M-6.3%	$29.1M-0.8%	$29.7M+1.2%	$29.0M-1.5%	$29.0M-5.2%	$29.3M-9.9%
Total Equity	-$66.2M-18.8%	-$67.9M-15.8%	-$63.6M-12.6%	-$59.5M-10.6%	-$55.7M+2.3%	-$58.6M-9.2%	-$56.5M-18.3%	-$53.8M-48.0%
Retained Earnings	-$272.1M-2.3%	-$273.4M-3.2%	-$270.1M-2.9%	-$268.1M-2.8%	-$266.0M-1.3%	-$264.9M-1.7%	-$262.6M-2.5%	-$260.8M-1.4%

Not reported in any period shown, so not listed: Goodwill.

EMMA Cash Flow Statement

EMMA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$4.0M	-$11K+99.5%	-$2.3M-52.1%	-$1.5M+70.4%	-$5.1M-304.5%	-$1.3M+48.8%	-$2.5M+45.8%	-$4.5M+19.7%	-$5.6M-17.6%	-$4.8M	N/A	-$2.2M+34.1%	-$3.3M-7.7%	-$3.0M	N/A	-$3.6M
Depreciation & Amortization	N/A	$39K+77.3%	$22K-31.3%	$32K-39.6%	$53K-10.2%	$59K-1.7%	$60K-17.8%	$73K+19.7%	$61K+25.3%	$49K+576.4%	$7K-5.3%	$8K-26.2%	$10K-20.8%	$13K-30.9%	$19K	N/A
Stock-Based Compensation	N/A	$25K-90.2%	$256K-79.7%	$1.3M+7787.5%	$16K-97.1%	$553K-25.2%	$739K	N/A	$1.6M-23.9%	$2.1M+149.9%	$835K+245.3%	$242K-76.0%	$1.0M-19.8%	$1.3M-6.9%	$1.4M-15.9%	$1.6M
Capital Expenditures	N/A	$1K-91.7%	$12K-29.4%	$17K-34.6%	$26K-64.4%	$73K+386.7%	$15K-75.0%	$60K-36.2%	$94K-26.5%	$128K+3097.5%	$4K	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	-$12K+99.5%	-$2.3M-51.2%	-$1.5M+70.2%	-$5.1M-284.3%	-$1.3M+46.2%	-$2.5M+46.2%	-$4.6M+20.0%	-$5.7M-16.4%	-$4.9M	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$1.6M	$2.2M-13.2%	$2.5M+678.7%	-$432K+81.9%	-$2.4M+62.6%	-$6.4M-216.6%	$5.5M+468.6%	-$1.5M+80.1%	-$7.4M-1451.6%	-$480K-482.6%	-$82K	N/A	$0-100.0%	$1K+105.5%	-$26K-18.1%	-$22K
Financing Cash Flow	-$3.6M	-$1.4M-5.3%	-$1.4M-154.6%	$2.5M-65.8%	$7.2M-2.4%	$7.4M+420.8%	-$2.3M-159.5%	$3.9M+169.6%	-$5.6M-153.6%	$10.4M	N/A	N/A	$3.3M-22.9%	$4.3M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$1.7M+158.2%	-$344K-223.3%	$2.2M+544.0%	$409K+176.4%	-$2.9M+0.3%	$279K+99.3%	$343K-66.9%	$148K+155.2%
Depreciation & Amortization	$14K+250.0%	$15K+200.0%	$15K+200.0%	$15K+200.0%	$4K-33.3%	$5K-16.7%	$5K-28.6%	$5K-28.6%
Stock-Based Compensation	N/A	$1K-90.0%	N/A	N/A	N/A	$10K-94.1%	N/A	N/A
Capital Expenditures	N/A	N/A	$0-100.0%	$0-100.0%	N/A	N/A	$6K0.0%	-$1K
Free Cash Flow	N/A	N/A	$2.2M+555.5%	$409K+178.2%	N/A	N/A	$337K-67.3%	$147K+153.4%
Investing Cash Flow	$1.6M-27.3%	$0	$0+100.0%	$0-100.0%	$2.2M-13.3%	$0+100.0%	-$2K+66.7%	$1K+100.3%
Financing Cash Flow	-$1.5M-640.5%	-$702K-103.5%	-$362K-85.6%	-$1.0M-128.8%	$284K+20.9%	-$345K+63.9%	-$195K-3800.0%	-$438K-188.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

EMMA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EMMA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	93.1%+0.3pp	92.8%-2.7pp	95.5%+9.5pp	85.9%+2.0pp	83.9%-6.4pp	90.3%-4.9pp	95.2%+1.2pp	94.0%+35.6pp	58.4%-35.2pp	93.5%-1.6pp	95.1%+49.1pp	46.0%	N/A	N/A	N/A
Operating Margin	1.8%+13.2pp	-11.4%-23.3pp	12.0%+47.8pp	-35.8%-6.1pp	-29.7%-29.6pp	-0.1%+19.7pp	-19.8%+31.5pp	-51.4%	-5528.1%	N/A	-2647.2%	-2825.2%	-3209.0%	N/A	N/A
Net Margin	-60.2%-21.4pp	-38.8%-26.1pp	-12.6%+45.2pp	-57.8%+19.6pp	-77.4%-83.2pp	5.8%	-241.0%	-441.0%	-5535.3%	N/A	N/A	-1971.0%	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-156.4%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-34.9%-7.6pp	-27.3%-16.7pp	-10.6%+11.4pp	-22.0%+6.1pp	-28.1%-30.4pp	2.3%+94.5pp	-92.2%+4.2pp	-96.4%+20.3pp	-116.7%	N/A	N/A	-199.3%	N/A	N/A	N/A
Current Ratio	0.110.0x	0.11-0.1x	0.19+0.1x	0.12-0.1x	0.24-0.2x	0.48-0.8x	1.26-0.1x	1.33-2.4x	3.68+3.4x	0.260.0x	0.30-0.5x	0.81+0.4x	0.38+0.4x	0.010.0x	0.03
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.12	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.58-0.1x	0.71-0.1x	0.84+0.5x	0.380.0x	0.360.0x	0.390.0x	0.38+0.2x	0.22+0.2x	0.02-0.1x	0.170.0x	0.18+0.1x	0.100.0x	0.09	N/A	2.02
FCF Margin	-0.1%+13.7pp	-13.8%-8.7pp	-5.1%+22.6pp	-27.7%-21.3pp	-6.4%+4.2pp	-10.6%+9.5pp	-20.1%+14.7pp	-34.8%	-3828.8%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	94.6%-0.1pp	91.5%+0.9pp	93.9%+3.3pp	92.7%-0.1pp	94.7%-0.8pp	90.6%+0.9pp	90.6%-6.7pp	92.8%-2.9pp
Operating Margin	60.0%+73.1pp	-41.5%-0.8pp	23.0%+39.9pp	20.6%+5.6pp	-13.1%-23.9pp	-40.7%	-16.9%-36.1pp	15.0%+14.5pp
Net Margin	21.2%+61.5pp	-168.3%	-50.6%+2.5pp	-61.5%-94.8pp	-40.3%+0.3pp	-96.8%	-53.1%-70.2pp	33.4%+32.0pp
Return on Assets	8.2%+13.0pp	-17.8%-7.5pp	-9.1%-1.7pp	-10.0%-16.7pp	-4.9%+3.6pp	-10.4%+4.3pp	-7.4%-10.8pp	6.7%+6.5pp
Current Ratio	0.090.0x	0.090.0x	0.110.0x	0.07-0.1x	0.08-0.1x	0.090.0x	0.11-0.1x	0.140.0x
Asset Turnover	0.39+0.3x	0.110.0x	0.180.0x	0.160.0x	0.12-0.1x	0.110.0x	0.14-0.1x	0.20+0.1x
FCF Margin	N/A	N/A	57.4%+47.1pp	12.1%+9.4pp	N/A	N/A	10.2%-4.3pp	2.7%+1.5pp

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Note: Shareholder equity is negative (-$63.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.11), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
EMMAUS LIFE SCIENCES INC EMMA	FY2025	$12.5M	-$7.5M	-60.2%	$4.1M	—
HEPION PHARMS INC HEPA	FY2025	N/A	-$8.3M	N/A	$12.8M	—
REGENERATIVE MEDICAL TECH RMTG	FY2025	$5.1M	-$7.8M	N/A	$548K	—
REGEN BIOPHARMA INC RGBP	FY2025	$237K	-$1.3M	N/A	$168K	—
LADRX CORPORATION LADX	FY2024	N/A	-$1.6M	N/A	$579K	—

Where EMMAUS LIFE SCIENCES INC Ranks

Frequently Asked Questions

What is EMMAUS LIFE SCIENCES INC's annual revenue?

EMMAUS LIFE SCIENCES INC (EMMA) reported $12.5M in total revenue for fiscal year 2025. This represents a -25.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is EMMAUS LIFE SCIENCES INC's revenue growing?

EMMAUS LIFE SCIENCES INC (EMMA) revenue declined by 25.2% year-over-year, from $16.7M to $12.5M in fiscal year 2025.

Is EMMAUS LIFE SCIENCES INC profitable?

No, EMMAUS LIFE SCIENCES INC (EMMA) reported a net income of -$7.5M in fiscal year 2025, with a net profit margin of -60.2%.

What is EMMAUS LIFE SCIENCES INC's EBITDA?

EMMAUS LIFE SCIENCES INC (EMMA) had EBITDA of $270K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does EMMAUS LIFE SCIENCES INC have?

As of fiscal year 2025, EMMAUS LIFE SCIENCES INC (EMMA) had $2.1M in cash and equivalents against $27.1M in long-term debt.

What is EMMAUS LIFE SCIENCES INC's gross margin?

EMMAUS LIFE SCIENCES INC (EMMA) had a gross margin of 93.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is EMMAUS LIFE SCIENCES INC's operating margin?

EMMAUS LIFE SCIENCES INC (EMMA) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is EMMAUS LIFE SCIENCES INC's net profit margin?

EMMAUS LIFE SCIENCES INC (EMMA) had a net profit margin of -60.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is EMMAUS LIFE SCIENCES INC's free cash flow?

EMMAUS LIFE SCIENCES INC (EMMA) recorded an outflow of $12K in free cash flow during fiscal year 2025. This represents a 99.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is EMMAUS LIFE SCIENCES INC's operating cash flow?

EMMAUS LIFE SCIENCES INC (EMMA) recorded an outflow of $11K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are EMMAUS LIFE SCIENCES INC's total assets?

EMMAUS LIFE SCIENCES INC (EMMA) had $21.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are EMMAUS LIFE SCIENCES INC's capital expenditures?

EMMAUS LIFE SCIENCES INC (EMMA) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does EMMAUS LIFE SCIENCES INC spend on research and development?

EMMAUS LIFE SCIENCES INC (EMMA) invested $313K in research and development during fiscal year 2025.

How many shares does EMMAUS LIFE SCIENCES INC have outstanding?

EMMAUS LIFE SCIENCES INC (EMMA) had 70M shares outstanding as of fiscal year 2025.

What is EMMAUS LIFE SCIENCES INC's current ratio?

EMMAUS LIFE SCIENCES INC (EMMA) had a current ratio of 0.11 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is EMMAUS LIFE SCIENCES INC's return on assets (ROA)?

EMMAUS LIFE SCIENCES INC (EMMA) had a return on assets of -34.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is EMMAUS LIFE SCIENCES INC's P/E ratio?

EMMAUS LIFE SCIENCES INC (EMMA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $4.1M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is EMMAUS LIFE SCIENCES INC's price-to-sales ratio?

EMMAUS LIFE SCIENCES INC (EMMA) trades at 0.3x sales, its market capitalization divided by revenue of $15.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $4.1M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is EMMAUS LIFE SCIENCES INC's debt-to-equity ratio negative or not reported?

EMMAUS LIFE SCIENCES INC (EMMA) has negative shareholder equity of -$63.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is EMMAUS LIFE SCIENCES INC's Altman Z-Score?

EMMAUS LIFE SCIENCES INC (EMMA) has an Altman Z-Score of -20.43, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is EMMAUS LIFE SCIENCES INC's Piotroski F-Score?

EMMAUS LIFE SCIENCES INC (EMMA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are EMMAUS LIFE SCIENCES INC's earnings high quality?

EMMAUS LIFE SCIENCES INC (EMMA) reported a net loss of $7.5M while operations used $11K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can EMMAUS LIFE SCIENCES INC cover its interest payments?

EMMAUS LIFE SCIENCES INC (EMMA) has an interest coverage ratio of 0.03x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.